Summary of clinical responses for the intent-to-treat population (N = 222)
| Response, no. (%) . | Patients treated with lenalidomide, N = 222 . | Patients with 2 or fewer prior treatment regimens, n = 73 . | Patients with 3 or more prior treatment regimens, n = 149 . | Patients with prior thalidomide treatment, n = 177 . | Patients with prior bortezomib treatment, n = 96 . |
|---|---|---|---|---|---|
| Complete response (CR) | 5 (2) | 1 (1) | 4 (3) | 3 (2) | 3 (3) |
| Partial response (PR) | 53 (24) | 18 (25) | 35 (23) | 38 (22) | 27 (28) |
| Minimal response (MR) | 40 (18) | 14 (19) | 26 (17) | 31 (18) | 14 (15) |
| Stable disease | 107 (48) | 35 (48) | 72 (48) | 90 (51) | 41 (43) |
| Progressive disease | 8 (4) | 1 (1) | 7 (5) | 8 (5) | 7 (7) |
| Not evaluable/known | 9 (4) | 4 (5) | 5 (3) | 7 (4) | 4 (4) |
| CR + PR | 58 (26) | 19 (26) | 39 (26) | 41 (23) | 30 (31) |
| CR + PR + MR | 98 (44) | 33 (45) | 65 (44) | 72 (41) | 44 (46) |
| Response, no. (%) . | Patients treated with lenalidomide, N = 222 . | Patients with 2 or fewer prior treatment regimens, n = 73 . | Patients with 3 or more prior treatment regimens, n = 149 . | Patients with prior thalidomide treatment, n = 177 . | Patients with prior bortezomib treatment, n = 96 . |
|---|---|---|---|---|---|
| Complete response (CR) | 5 (2) | 1 (1) | 4 (3) | 3 (2) | 3 (3) |
| Partial response (PR) | 53 (24) | 18 (25) | 35 (23) | 38 (22) | 27 (28) |
| Minimal response (MR) | 40 (18) | 14 (19) | 26 (17) | 31 (18) | 14 (15) |
| Stable disease | 107 (48) | 35 (48) | 72 (48) | 90 (51) | 41 (43) |
| Progressive disease | 8 (4) | 1 (1) | 7 (5) | 8 (5) | 7 (7) |
| Not evaluable/known | 9 (4) | 4 (5) | 5 (3) | 7 (4) | 4 (4) |
| CR + PR | 58 (26) | 19 (26) | 39 (26) | 41 (23) | 30 (31) |
| CR + PR + MR | 98 (44) | 33 (45) | 65 (44) | 72 (41) | 44 (46) |